Tuyển tập báo cáo các nghiên cứu khoa học quốc tế ngành y học dành cho các bạn tham khảo đề tài: Phosphodiesterase 5 inhibitors lower both portal and pulmonary pressure in portopulmonary hypertension: a case report. | Journal of Medical Case Reports BioMed Central Open Access Case report Phosphodiesterase 5 inhibitors lower both portal and pulmonary pressure in portopulmonary hypertension a case report Hinrich C Bremer1 Wolfgang Kreisel 2 Kai Roecker3 Michael Dreher1 Daniel Koenig3 Anna Katharina Kurz-Schmieg2 Hubert E Blum2 Martin Roessle4 and Peter Deibert3 Address Department of Pneumology University Hospital Freiburg Germany 2Department of Gastroenterology Hepatology Endocrinology and Infectious Diseases University Hospital Freiburg Germany 3Department of Rehabilitative and Preventive Sports Medicine University Hospital Freiburg Germany and 4Gastrointestinal and Endocrinological Center Freiburg Germany Email Hinrich C Bremer - Wolfgang Kreisel - Kai Michael Dreher - Daniel Koenig - Anna Katharina Kurz-Schmieg - kurz@ Hubert E Blum - Martin Roessle - martin-roessle@ Peter Deibert - Corresponding author Published 10 July 2007 Received 20 March 2007 Journal of Medical Case Reports 2007 1 46 doi 1752-1947-1-46 Accepted 10 July 2007 This article is available from http content 1 1 46 2007 Bremer et al licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License http licenses by which permits unrestricted use distribution and reproduction in any medium provided the original work is properly cited. Abstract Background Portopulmonary hypertension PPHTN is a severe complication in liver cirrhosis. PDE5 inhibitors lower pulmonary arterial pressure PAP in PPHTN. However their effect on portal
